| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 8384 | 2010 |
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ... New England Journal of Medicine 353 (16), 1659-1672, 2005 | 6730 | 2005 |
| Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability A Umar, CR Boland, JP Terdiman, S Syngal, A Chapelle, J Rüschoff, ... Journal of the National Cancer Institute 96 (4), 261-268, 2004 | 3938 | 2004 |
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study M Hofmann, O Stoss, D Shi, R Büttner, M Van De Vijver, W Kim, A Ochiai, ... Histopathology 52 (7), 797-805, 2008 | 1544 | 2008 |
| Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression W Dietmaier, S Wallinger, T Bocker, F Kullmann, R Fishel, J Rüschoff Cancer research 57 (21), 4749-4756, 1997 | 951 | 1997 |
| HER2 testing in gastric cancer: a practical approach J Rüschoff, W Hanna, M Bilous, M Hofmann, RY Osamura, ... Modern Pathology 25 (5), 637-650, 2012 | 671 | 2012 |
| HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing J Rüschoff, M Dietel, G Baretton, S Arbogast, A Walch, G Monges, ... Virchows Archiv 457, 299-307, 2010 | 622 | 2010 |
| HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer E Van Cutsem, YJ Bang, F Feng-Yi, JM Xu, KW Lee, SC Jiao, JL Chong, ... Gastric cancer 18, 476-484, 2015 | 606 | 2015 |
| Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas AH Scheel, M Dietel, LC Heukamp, K Jöhrens, T Kirchner, S Reu, ... Modern Pathology 29 (10), 1165-1172, 2016 | 408 | 2016 |
| Multiple mutation analyses in single tumor cells with improved whole genome amplification W Dietmaier, A Hartmann, S Wallinger, E Heinmöller, T Kerner, E Endl, ... The American journal of pathology 154 (1), 83-95, 1999 | 406 | 1999 |
| ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... Lancet 376 (9742), 687-697, 2010 | 372 | 2010 |
| Current perspectives on HER2 testing: a review of national testing guidelines M Bilous, M Dowsett, W Hanna, J Isola, A Lebeau, A Moreno, ... Modern pathology 16 (2), 173-182, 2003 | 357 | 2003 |
| HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity WM Hanna, J Rüschoff, M Bilous, RA Coudry, M Dowsett, RY Osamura, ... Modern Pathology 27 (1), 4-18, 2014 | 345 | 2014 |
| Enhancement of experimental metastasis by tumor necrosis factor. P Orosz, B Echtenacher, W Falk, J Rüschoff, D Weber, DN Männel The Journal of experimental medicine 177 (5), 1391-1398, 1993 | 284 | 1993 |
| Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA … Y Bang, H Chung, J Xu, F Lordick, A Sawaki, N Al-Sakaff, O Lipatov, ... Journal of Clinical Oncology 27 (15_suppl), 4556-4556, 2009 | 262 | 2009 |
| Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer M Roeßler, W Rollinger, S Palme, ML Hagmann, P Berndt, AM Engel, ... Clinical cancer research 11 (18), 6550-6557, 2005 | 237 | 2005 |
| HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin P Heinmöller, C Gross, K Beyser, C Schmidtgen, G Maass, M Pedrocchi, ... Clinical Cancer Research 9 (14), 5238-5243, 2003 | 232 | 2003 |
| Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection J Rüschoff, S Wallinger, W Dietmaier, T Bocker, G Brockhoff, F Hofstädter, ... Proceedings of the National Academy of Sciences 95 (19), 11301-11306, 1998 | 230 | 1998 |
| HNPCC-associated small bowel cancer: clinical and molecular characteristics K Schulmann, FE Brasch, E Kunstmann, C Engel, C Pagenstecher, ... Gastroenterology 128 (3), 590-599, 2005 | 223 | 2005 |
| Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The … M Dowsett, M Procter, W McCaskill-Stevens, E de Azambuja, U Dafni, ... Journal of clinical oncology 27 (18), 2962-2969, 2009 | 216 | 2009 |
